Sarah W. Baron

Sarah W. Baron

Auto-generated profile, based on publicly available information

Sarah W. Baron

Montefiore Med Ctr, Div Hosp Med, Dept Med, Bronx, NY USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2019 in BMJ Quality & Safety
Verified
Journal Article
Closed access
PDF file
BGBenjamin Galen
Benjamin Galen
SBSarah Baron
Sarah Baron
SYSandra Young
Sandra Young
AHAlleyne Hall
Alleyne Hall
LBLinda Berger-Spivack
Linda Berger-Spivack
WSWilliam Southern
William Southern
Background Training nurses in ultrasound-guided peripheral intravenous catheter placement might reduce the use of more invasive venous access devices (peripherally inserted central catheters (PICC) and midline catheters). Methods We implemented an abbreviated training in ultrasound-guided peripheral intravenous catheter placement for nurses on an inpatient medical unit and provided a portable ultrasound device for 10 months. Results Nurses on this unit placed 99 ultrasound-guided peripheral intravenous catheters with a high level of success. During the implementation period, PICC and midline catheter placement decreased from a mean 4.8 to 2.5 per month, meeting criteria for special cause variation. In the postimplementation period, the average catheter use reverted to 4.3 per month on the intervention unit. A comparison inpatient medical unit without training or access to a portable ultrasound device experienced no significant change in PICC and midline catheter use throughout the study period (mean of 6.0 per month). Conclusions These results suggest that an abbreviated training in ultrasound-guided peripheral intravenous catheter placement for nurses on an inpatient medical unit is sufficient to reduce PICC and midline catheters.

11 December 2019 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Closed access
PDF file
SBSarah W. Baron
Sarah W. Baron
BOBelinda E. Ostrowsky
Belinda E. Ostrowsky
PNPriya Nori
Priya Nori
DDDavid Y. Drory
David Y. Drory
MLMichael H. Levi
Michael H. Levi
WSWilliam N. Southern
William N. Southern
Objective: Efforts to reduceClostridioides difficileinfection (CDI) have targeted transmission from patients with symptomaticC. difficile. However, many patients with theC. difficileorganism are carriers without symptoms who may serve as reservoirs for spread of infection and may be at risk for progression to symptomaticC. difficile. To estimate the prevalence ofC. difficilecarriage and determine the risk and speed of progression to symptomaticC. difficileamong carriers, we established a pilot screening program in a large urban hospital.Design: Prospective cohort study.Setting: An 800-bed, tertiary-care, academic medical center in the Bronx, New York.Participants: A sample of admitted adults without diarrhea, with oversampling of nursing facility patients.Methods: Perirectal swabs were tested by polymerase chain reaction forC. difficilewithin 24 hours of admission, and patients were followed for progression to symptomaticC. difficile. Development of symptomaticC. difficilewas compared amongC. difficilecarriers and noncarriers using a Cox proportional hazards model.Results: Of the 220 subjects, 21 (9.6%) wereC. difficilecarriers, including 10.2% of the nursing facility residents and 7.7% of the community residents (P= .60). Among the 21C. difficilecarriers, 8 (38.1%) progressed to symptomaticC. difficile, but only 4 (2.0%) of the 199 noncarriers progressed to symptomaticC. difficile(hazard ratio, 23.9; 95% CI, 7.2–79.6;P< .0001).Conclusions: Asymptomatic carriage ofC. difficileis prevalent among admitted patients and confers a significant risk of progression to symptomatic CDI. Screening for asymptomatic carriers may represent an opportunity to reduce CDI.

5 March 2021 in Transfusion
Verified
Journal Article
Open access
PDF file
JSJames Szymanski
James Szymanski
LMLaurel Mohrmann
Laurel Mohrmann
JCJamal Carter
Jamal Carter
RNRandin Nelson
Randin Nelson
SCSweta Chekuri
Sweta Chekuri
MPMonika Paroder
Monika Paroder
Background Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has a variable clinical course with significant mortality. Early reports suggested higher rates of SARS‐CoV‐2 infection in patients with type A blood and enrichment of type A individuals among COVID‐19 mortalities. Study Design and Methods The study includes all patients hospitalized or with an emergency department (ED) visit who were tested for SARS‐CoV‐2 between March 10, 2020 and June 8, 2020 and had a positive test result by nucleic acid test (NAT) performed on a nasopharyngeal swab specimen. A total of 4968 patients met the study inclusion criteria, with a subsequent 23.1% (n = 1146/4968) all‐cause mortality rate in the study cohort. To estimate overall risk by ABO type and account for the competing risks of in‐hospital mortality and discharge, we calculated the cumulative incidence function (CIF) for each event. Cause‐specific hazard ratios (csHRs) for in‐hospital mortality and discharge were analyzed using multivariable Cox proportional hazards models. Results Type A blood was associated with the increased cause‐specific hazard of death among COVID‐19 patients compared to type O (HR = 1.17, 1.02–1.33, p = .02) and type B (HR = 1.32,1.10–1.58, p = .003). Conclusions Our study shows that ABO histo‐blood group type is associated with the risk of in‐hospital death in COVID‐19 patients, warranting additional inquiry. Elucidating the mechanism behind this association may reveal insights into the susceptibility and/or immunity to SARS‐CoV‐2.

12 August 2020 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Open access
ACArthur J. Chang
Arthur J. Chang
MCMichael Croix
Michael Croix
PKPatrick Kenney
Patrick Kenney
SBSarah Bs Baron
Sarah Bs Baron
MHMark Hicar
Mark Hicar
With recent reports showing clinical and laboratory overlap of multisystem inflammatory syndrome in children and Kawasaki disease (KD), we addressed the hypothesis that cross coronavirus humoral immunity leads to a parallel postinfectious phenomenon explaining similar pathologic findings in KD and multisystem inflammatory syndrome in children. We demonstrated no cross-reactivity in children with KD but observed some nonspecific interactions postintravenous immunoglobulin infusion.

21 June 2022 in Journal of Hospital Medicine
Verified
Journal Article
Closed access
SBSarah W. Baron
Sarah W. Baron
PYPei‐Chun Yu
Pei‐Chun Yu
PIPeter B. Imrey
Peter B. Imrey
WSWilliam N. Southern
William N. Southern
ADAbhishek Deshpande
Abhishek Deshpande
MRMichael B. Rothberg
Michael B. Rothberg

15 August 2024 in Journal of Substance Use and Addiction Treatment
Verified
Journal Article
Closed access
SBSarah W. Baron
Sarah W. Baron
JWJonathan M. Wai
Jonathan M. Wai
CAChristopher Aloezos
Christopher Aloezos
RCRegina Cregin
Regina Cregin
JCJeffrey Ceresnak
Jeffrey Ceresnak
WSWilliam N. Southern
William N. Southern